C12N 2740/16234
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2740/16234 (Use of virus or viral component as vaccine) appears on 281 US grants and 488 published applications in this corpus.
Search patents in C12N- Granted patents
- 281
- Published applications
- 488
- Assignees
- 245
- Inventors
- 788
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 2 | 0 |
| 1998 | 7 | 0 |
| 1999 | 5 | 0 |
| 2000 | 3 | 0 |
| 2001 | 2 | 3 |
| 2002 | 6 | 14 |
| 2003 | 4 | 15 |
| 2004 | 7 | 30 |
| 2005 | 5 | 23 |
| 2006 | 5 | 22 |
| 2007 | 4 | 21 |
| 2008 | 8 | 18 |
| 2009 | 9 | 22 |
| 2010 | 6 | 19 |
| 2011 | 9 | 18 |
| 2012 | 14 | 30 |
| 2013 | 8 | 16 |
| 2014 | 16 | 15 |
| 2015 | 15 | 23 |
| 2016 | 15 | 29 |
| 2017 | 22 | 31 |
| 2018 | 16 | 23 |
| 2019 | 19 | 23 |
| 2020 | 13 | 11 |
| 2021 | 14 | 18 |
| 2022 | 17 | 26 |
| 2023 | 8 | 10 |
| 2024 | 8 | 11 |
| 2025 | 4 | 11 |
| 2026 | 8 | 6 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods and compositions for inducing an immune response using conserved element constructs18 Aug 2026US 12,709,635 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- HIV immunotherapy with no pre-immunization step18 Aug 2026US 12,709,753 B2American Gene Technologies International Inc.
- Infectious disease antigens and vaccines5 May 2026US 12,616,746 B2Seattle Project Corp.
- Persistent memory T-cell responses to cancer and infectious-disease antigens by manipulation of amino acid-catabolism pathways24 Mar 2026US 12,582,709 B2The Regents of the University of California
- Targeting moDC to enhance vaccine efficacy on mucosal surface10 Mar 2026US 12,569,557 B2University of Florida Research Foundation, Inc.
- Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases6 Aug 2026US 2026/0224687 A1Centre National De La Recherche Scientifique
- Directed evolution of engineered virus-like particles (evlps)23 Jul 2026US 2026/0209747 A1President and Fellows of Harvard College
- Highly networked immunogen composition14 May 2026US 2026/0130984 A1Massachusetts Eye and Ear Infirmary
- Targeting modc to enhance vaccine efficacy on mucosal surface12 Mar 2026US 2026/0069685 A1
- Method of treatment of hiv infection with vaccine5 Mar 2026US 2026/0063627 A1Gilead Sciences, Inc.
Most cited
By later US patents
- Genetic immunization277US 5,593,972 AThe Trustees of the University of Pennsylvania · 1997
- Compositions and methods for delivery of genetic material184US 5,739,118 AApollon Inc. · 1998
- Genetic immunization137US 5,817,637 AThe Trustees of the University of Pennsylvania · 1998
- Compositions and methods for delivery of genetic material132US 5,962,428 AApollon Inc. · 1999
- Genetic immunization117US 5,830,876 AThe Trustees of the University of Pennsylvania · 1998